Navigation Links
Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
Date:6/28/2010

age 12 to 45 with new-onset type 1 diabetes. In the confirmatory study, otelixizumab is administered as a single course, given not more than 90 days after the initial diagnosis of autoimmune type 1 diabetes.  The primary endpoint will be a measurement of C-peptide, a surrogate measure of beta cell function that has been endorsed by the U.S. Food and Drug Administration (FDA) at 12 months after dosing.  Maintenance of beta cell function has been associated with improved glycemic control (HbA1c levels), fewer hypoglycemic events, fewer hyperglycemic excursions, and a reduction in long-term disease complications in established type 1 diabetes patients, as referenced in the Diabetes Control and Complications Trial (DCCT).

"Tolerx is aggressively moving forward in our clinical development of otelixizumab.  We are excited by the potential of this novel drug candidate to change the type 1 diabetes treatment paradigm by inhibiting disease progression and perhaps halting the disease by inducing an immunologic remission," said Dr. Douglas J. Ringler, President and Chief Executive Officer of Tolerx.  "The first patients have been dosed in the DEFEND-2 study, and we believe our study is designed with the robustness and rigor to confirm the efficacy and safety of otelixizumab in a broad patient population."

For additional information about DEFEND-2, please visit www.DefendAgainstDiabetes.com.

About Type 1 Diabetes

Diabetes (medically known as diabetes mellitus) is the name given to disorders in which the body has difficulty regulating its blood glucose (sugar) level. Ther
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
5. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
6. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
7. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
8. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Professional Compounding Centers of America ... awarding the three best scientific presentations at the ... . The Formulating Better Medicines for Children ... Athens, Greece , includes dozens of ... from which three winners will be selected by ...
(Date:8/21/2014)... PARK, Calif. , Aug. 21, 2014 ... in the emerging field of regenerative medicine, announced today ... Ricciardi to the Company,s newly expanded Board of Directors. ... comprises eight directors, three of whom are independent. ... of experience working with emerging growth companies. He is ...
(Date:8/20/2014)... , Aug. 20, 2014 The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kansas blocked the sale of ...
Breaking Medicine Technology:Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
(Date:8/21/2014)... August 21, 2014 Recently, Van ... their patients. Alternative medicine is on the rise ... millenials. According to The Fiscal Times, young people ... over conventional medicine. , The Fiscal Times published ... millenials are embracing alternative medicine. The article can ...
(Date:8/21/2014)... Pulmonary Hypertension Association goes on ... for PH patients and families to help fight ... Association – the country’s leading pulmonary hypertension ... and cure pulmonary hypertension (PH) – a disease ... the heart and can lead right to heart ...
(Date:8/21/2014)... California (PRWEB) August 21, 2014 The ... initial plans for entertainment and programming for its inaugural ... On Sunday, October 12, 2014, from 11 a.m. to ... closed to all cars and the downtown will be ... activities, curated by Community Arts Resources (CARS), for all ...
(Date:8/21/2014)... Dennis Thompson HealthDay Reporter ... combination of therapy and antidepressants appears to best help ... reports. Four out of five people suffering from ... recovery when treated with cognitive therapy plus antidepressant medication, ... didn,t work much better than drugs alone in helping ...
(Date:8/21/2014)... To sexually objectify a woman is to focus on ... sexual pleasure rather than viewing her as a complete ... long been considered a problem in the media, how ... in Psychology of Women Quarterly , a SAGE ... body is related to higher incidents of sexual pressure ...
Breaking Medicine News(10 mins):Health News:Van Uden Center Sees Growth in Alternative Medicine 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3Health News:Objectification in romantic relationships related to sexual pressure and coercion 2
... FORT WORTH, Texas, Nov. 11 Wound Management ... Management Technologies Division will search for partners to ... to develop opportunities within the International Biotechnology and ... developments concerning advisory board appointments, research affiliations, and ...
... FAIRFAX, Va.Catheter-directed therapy or catheter-directed thrombolysisan interventional radiology ... specially designed catheters to dissolve dangerous blood clots ... a first-line treatment option for massive pulmonary embolism, ... Vascular and Interventional Radiology . "Modern ...
... ... announces new research focusing on Employee Engagement, Revenue and the New Economy as kickoff ... ... 12, 2009 -- There is little else more pressing in business than the financial ...
... ... decades The American Red Cross is making available for sale to the ... and bound journals, antique uniforms (1925 – 1941), flags, vintage ... a model train, photographs (including those of the founder Clara Barton, past ...
... The Quigley Corporation, (Nasdaq: QGLY) , ... a conference call in which Ted Karkus, Chairman and CEO, will ... results and Q&A. , The conference call will be ... www.quigleyco.com ), at 11:00 AM (ET) on Thursday, November 12, ...
... , LONDON, Nov. 11 The healthcare market is ... the global economic slowdown. Costs for healthcare are reaching ... exception. Market players in this industry have been faced ... technological advancements in hardware, high replacement costs, exchange rates ...
Cached Medicine News:Health News:OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners 2Health News:OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners 3Health News:When seconds count: Interventional radiology treatment for pulmonary embolism saves lives 2Health News:When seconds count: Interventional radiology treatment for pulmonary embolism saves lives 3Health News:Performance Connections International Announces New Research Focusing on the Impact of Employee Engagement in the New Economy 2Health News:Performance Connections International Announces New Research Focusing on the Impact of Employee Engagement in the New Economy 3Health News:American Red Cross Auctions Historical Artifacts Through OLS Trading, Inc 2Health News:American Red Cross Auctions Historical Artifacts Through OLS Trading, Inc 3Health News:The Quigley Corporation to Host Conference Call to Review Third Quarter Results and Provide Company Update 2Health News:Frost & Sullivan to Hold Analyst Briefing on the European Neurophysiological Monitoring Market, the Golden Standard in Patient Safety 2Health News:Frost & Sullivan to Hold Analyst Briefing on the European Neurophysiological Monitoring Market, the Golden Standard in Patient Safety 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: